Bone density and alendronate effects in Duchenne muscular dystrophy patients.

Muscle Nerve

Division of Endocrinology, E 426 GH, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, Iowa, 52242, USA.

Published: April 2014

Introduction: Patients with DMD have low bone mineral density (BMD) and are at high risk for fractures. We examined changes in BMD and the effects of alendronate in DMD patients treated at our institution in the last decade.

Methods: Retrospective cohort study of 39 DMD patients.

Results: Patients had screening dual energy x-ray absorptiometry (DXA) at an average age of 12 years. The vast majority had low Z-scores at the total hip and lumbar spine. Patients treated with glucocorticoids had a significantly lower Z-score at the spine than those not treated with glucocorticoids. Z-scores at the hip trended down without alendronate (P = 0.07) and trended up with alendronate (P = 0.4).

Conclusions: By age 12 years, most patients with DMD had low Z-scores. They may have benefitted from earlier screening. Z-score at the hip trended downward without alendronate and trended upward (stabilized) with alendronate, but these trends were not statistically significant.

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.23948DOI Listing

Publication Analysis

Top Keywords

patients dmd
8
dmd low
8
patients treated
8
age years
8
low z-scores
8
treated glucocorticoids
8
hip trended
8
trended alendronate
8
alendronate
6
patients
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!